These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 23418046

  • 1. Effects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: results of a phase 1, randomized, open-label trial.
    Doyle MK, Rahman MU, Frederick B, Birbara CA, de Vries D, Toedter G, Wu X, Chen D, Ranganath VK, Westerman ME, Furst DE.
    Rheumatology (Oxford); 2013 Jul; 52(7):1214-9. PubMed ID: 23418046
    [Abstract] [Full Text] [Related]

  • 2. E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy.
    Visvanathan S, Wagner C, Rojas J, Kay J, Dasgupta B, Matteson EL, Mack M, Baker DG, Rahman MU.
    J Rheumatol; 2009 Jul; 36(7):1371-9. PubMed ID: 19487269
    [Abstract] [Full Text] [Related]

  • 3. Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study.
    Zhuang Y, Xu Z, Frederick B, de Vries DE, Ford JA, Keen M, Doyle MK, Petty KJ, Davis HM, Zhou H.
    Clin Ther; 2012 Jan; 34(1):77-90. PubMed ID: 22169051
    [Abstract] [Full Text] [Related]

  • 4. Comparative evaluation of the effects of treatment with tocilizumab and TNF-α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients.
    Song SN, Iwahashi M, Tomosugi N, Uno K, Yamana J, Yamana S, Isobe T, Ito H, Kawabata H, Yoshizaki K.
    Arthritis Res Ther; 2013 Oct 02; 15(5):R141. PubMed ID: 24286116
    [Abstract] [Full Text] [Related]

  • 5. Effects of Alpha-Lipoic Acid Supplementation on Inflammatory Biomarkers and Matrix Metalloproteinase-3 in Rheumatoid Arthritis Patients.
    Mirtaheri E, Gargari BP, Kolahi S, Dehghan P, Asghari-Jafarabadi M, Hajalilou M, Shakiba Novin Z, Mesgari Abbasi M.
    J Am Coll Nutr; 2015 Oct 02; 34(4):310-7. PubMed ID: 25751300
    [Abstract] [Full Text] [Related]

  • 6. Serum pro-hepcidin could reflect disease activity in patients with rheumatoid arthritis.
    Kim HR, Kim KW, Yoon SY, Kim SH, Lee SH.
    J Korean Med Sci; 2010 Mar 02; 25(3):348-52. PubMed ID: 20191031
    [Abstract] [Full Text] [Related]

  • 7. Maintenance of efficacy and safety with subcutaneous golimumab among patients with active rheumatoid arthritis who previously received intravenous golimumab.
    Taylor PC, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu Z, Mack M, Kremer J.
    J Rheumatol; 2011 Dec 02; 38(12):2572-80. PubMed ID: 22089463
    [Abstract] [Full Text] [Related]

  • 8. Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation.
    Kirkham BW, Wasko MC, Hsia EC, Fleischmann RM, Genovese MC, Matteson EL, Liu H, Rahman MU.
    Ann Rheum Dis; 2014 Jan 02; 73(1):161-9. PubMed ID: 23300117
    [Abstract] [Full Text] [Related]

  • 9. Pharmacodynamic biomarkers and differential effects of TNF- and GM-CSF-targeting biologics in rheumatoid arthritis.
    Guo X, Wang S, Godwood A, Close D, Ryan PC, Roskos LK, White WI.
    Int J Rheum Dis; 2019 Apr 02; 22(4):646-653. PubMed ID: 30358109
    [Abstract] [Full Text] [Related]

  • 10. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, Visvanathan S, Hsia EC, Rahman MU, GO-AFTER study investigators.
    Lancet; 2009 Jul 18; 374(9685):210-21. PubMed ID: 19560810
    [Abstract] [Full Text] [Related]

  • 11. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study.
    Kremer J, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu Z, Han J, Taylor P.
    Arthritis Rheum; 2010 Apr 18; 62(4):917-28. PubMed ID: 20131276
    [Abstract] [Full Text] [Related]

  • 12. Serum pro-hepcidin levels in rheumatoid arthritis and systemic lupus erythematosus.
    Koca SS, Isik A, Ustundag B, Metin K, Aksoy K.
    Inflammation; 2008 Jun 18; 31(3):146-53. PubMed ID: 18278547
    [Abstract] [Full Text] [Related]

  • 13. Plasma Ferritin and Hepcidin Are Lower at 4 Months Postpartum among Women with Elevated C-Reactive Protein or α1-Acid Glycoprotein.
    Jorgensen JM, Yang Z, Lönnerdal B, Chantry CJ, Dewey KG.
    J Nutr; 2017 Jun 18; 147(6):1194-1199. PubMed ID: 28446628
    [Abstract] [Full Text] [Related]

  • 14. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade.
    Ingegnoli F, Fantini F, Favalli EG, Soldi A, Griffini S, Galbiati V, Meroni PL, Cugno M.
    J Autoimmun; 2008 Sep 18; 31(2):175-9. PubMed ID: 18707846
    [Abstract] [Full Text] [Related]

  • 15. Markers of inflammation are negatively correlated with serum leptin in rheumatoid arthritis.
    Popa C, Netea MG, Radstake TR, van Riel PL, Barrera P, van der Meer JW.
    Ann Rheum Dis; 2005 Aug 18; 64(8):1195-8. PubMed ID: 15731289
    [Abstract] [Full Text] [Related]

  • 16. Proinflammatory state, hepcidin, and anemia in older persons.
    Ferrucci L, Semba RD, Guralnik JM, Ershler WB, Bandinelli S, Patel KV, Sun K, Woodman RC, Andrews NC, Cotter RJ, Ganz T, Nemeth E, Longo DL.
    Blood; 2010 May 06; 115(18):3810-6. PubMed ID: 20081092
    [Abstract] [Full Text] [Related]

  • 17. Radiographic progression is associated with resolution of systemic inflammation in patients with axial spondylarthritis treated with tumor necrosis factor α inhibitors: a study of radiographic progression, inflammation on magnetic resonance imaging, and circulating biomarkers of inflammation, angiogenesis, and cartilage and bone turnover.
    Pedersen SJ, Sørensen IJ, Lambert RG, Hermann KG, Garnero P, Johansen JS, Madsen OR, Hansen A, Hansen MS, Thamsborg G, Andersen LS, Majgaard O, Loft AG, Erlendsson J, Asmussen KH, Jurik AG, Møller J, Hasselquist M, Mikkelsen D, Østergaard M.
    Arthritis Rheum; 2011 Dec 06; 63(12):3789-800. PubMed ID: 22127697
    [Abstract] [Full Text] [Related]

  • 18. Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes.
    Gabay C, Burmester GR, Strand V, Msihid J, Zilberstein M, Kimura T, van Hoogstraten H, Boklage SH, Sadeh J, Graham NMH, Boyapati A.
    Arthritis Res Ther; 2020 Apr 07; 22(1):70. PubMed ID: 32264972
    [Abstract] [Full Text] [Related]

  • 19. Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis.
    Isaacs JD, Harari O, Kobold U, Lee JS, Bernasconi C.
    Arthritis Res Ther; 2013 Apr 07; 15(6):R204. PubMed ID: 24295403
    [Abstract] [Full Text] [Related]

  • 20. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis.
    Klimiuk PA, Sierakowski S, Domyslawska I, Chwiecko J.
    J Rheumatol; 2004 Feb 07; 31(2):238-42. PubMed ID: 14760791
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.